Grant ID | DP240244 |
Awarded On | May 15, 2024 |
Title | 7HP935, an integrin agonist, to augment hematopoietic stem cell transplant for the treatment of hematologic malignancies |
Program | Product Development Research |
Award Mechanism | Texas Therapeutics Company Awards for Product Development Research |
Institution/Organization | 7 Hills Pharma Inc. |
Principal Investigator/Program Director | Lionel Lewis |
Cancer Sites | Leukemia |
Contracted Amount | $4,700,000 |
Lay Summary |
7 Hills Pharma is a Texas-based company developing novel therapies for cancer. Our drug, 7HP935, could benefit patients with leukemia, who require stem cell transplant. The curative potential of transplant is limited by timely access to a suitable donor and elevated risk of infection, particularly in Hispanic/Latino and Black patients, who comprise 51.8% of the Texas population. Umbilical cord blood (UCB) is a readily available, FDA approved stem cell source that has been shown to have curative potential but is limited by slow stem cell engraftment, resulting in high infection rates and extended hospital stays. 7HP935 is a potential drug that, given in combination with a stem cell transplan... |